Author response

John Ratchford; Kathleen Costello; Daniel Salo Reich; Peter A. Calabresi

doi:10.1212/01.wnl.0000432547.27815.74

Author response

John Ratchford, Kathleen Costello, Daniel Salo Reich, Peter A. Calabresi

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	306
Number of pages	1
Journal	Neurology
Volume	81
Issue number	3
DOIs	https://doi.org/10.1212/01.wnl.0000432547.27815.74
State	Published - Jul 16 2013

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/01.wnl.0000432547.27815.74

Cite this

@article{85c97fcb08354d558ead2fc0e8d9c9dc,

title = "Author response",

author = "John Ratchford and Kathleen Costello and Reich, {Daniel Salo} and Calabresi, {Peter A.}",

note = "Funding Information: Disclosure: J.N. Ratchford consulted for Bristol-Myers Squibb, received a speaking honorarium from Teva, and receives research funding for clinical trials from Novartis and Biogen Idec. K. Costello has consulted for Teva, Novartis, Biogen Idec, Sanofi-Aventis, and EMD-Serono. D.S. Reich's research is supported by the Intramural Research Program of the National Institute of Neurological Disorders and Stroke. P.A. Calabresi has provided consultation services to Novartis, Teva, Biogen Idec, Vertex, Vaccinex, Genentech; and has received grant support from EMD-Serono, Teva, Biogen Idec, Genentech, Bayer, Abbott, and Vertex. Go to Neurology.org for full disclosures. ",

year = "2013",

month = jul,

day = "16",

doi = "10.1212/01.wnl.0000432547.27815.74",

language = "English (US)",

volume = "81",

pages = "306",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Author response

AU - Ratchford, John

AU - Costello, Kathleen

AU - Reich, Daniel Salo

AU - Calabresi, Peter A.

N1 - Funding Information: Disclosure: J.N. Ratchford consulted for Bristol-Myers Squibb, received a speaking honorarium from Teva, and receives research funding for clinical trials from Novartis and Biogen Idec. K. Costello has consulted for Teva, Novartis, Biogen Idec, Sanofi-Aventis, and EMD-Serono. D.S. Reich's research is supported by the Intramural Research Program of the National Institute of Neurological Disorders and Stroke. P.A. Calabresi has provided consultation services to Novartis, Teva, Biogen Idec, Vertex, Vaccinex, Genentech; and has received grant support from EMD-Serono, Teva, Biogen Idec, Genentech, Bayer, Abbott, and Vertex. Go to Neurology.org for full disclosures.

PY - 2013/7/16

Y1 - 2013/7/16

UR - http://www.scopus.com/inward/record.url?scp=84881284676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881284676&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000432547.27815.74

DO - 10.1212/01.wnl.0000432547.27815.74

M3 - Comment/debate

C2 - 24024233

AN - SCOPUS:84881284676

SN - 0028-3878

VL - 81

SP - 306

JO - Neurology

JF - Neurology

IS - 3

ER -

Author response

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this